France
DeepLife, an innovative startup founded in 2019, is making significant strides in biotechnology by developing the first SaaS platform for creating a Digital Twin of cells. They leverage advanced AI and machine learning to transform cell engineering by simulating cell behavior in silico, aiming to complement traditional in vitro testing.
Based in France, DeepLife's platform integrates cutting-edge deep learning algorithms with multi-omics sequencing data and proprietary cell engineering tools. This provides an efficient path for biotech and pharmaceutical companies to accelerate target identification processes. Their collaborative approach extends to academia, enhancing credibility through published papers and open data access.
The company received a $10.00M Series A investment on 01 December 2024 from investors such as Groupe Prunay, Relyens Innovation Santé, YZR Capital, and Beiersdorf, showcasing robust financial backing and confidence in their pioneering technology.
Thymmune Therapeutics